Carbohydrate-binding antibodies play diverse and critical roles in human health. Endogenous carbohydrate-binding antibodies that recognize bacterial, fungal, and other microbial carbohydrates prevent systemic infections and help maintain microbiome homeostasis. Anti-glycan antibodies can have both beneficial and detrimental effects. For example, alloantibodies to ABO blood group carbohydrates can help reduce the spread of some infectious diseases, but they also impose limitations for blood transfusions. Antibodies that recognize self-glycans can contribute to autoimmune diseases, such as Guillain-Barre syndrome. In addition to endogenous antibodies that arise through natural processes, a variety of vaccines induce anti-glycan antibodies as a primary mechanism of protection. Some examples of approved carbohydrate-based vaccines that have had a major impact on human health are against pneumococcus, Haemophilus influeanza type b, and Neisseria meningitidis. Monoclonal antibodies specifically targeting pathogen associated or tumor associated carbohydrate antigens (TACAs) are used clinically for both diagnostic and therapeutic purposes. This review aims to highlight some of the well-studied and critically important applications of anti-carbohydrate antibodies.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
April 2021
-
Cover Image
Cover Image
Serine pyrophosphorylation by the inositol pyrophosphate 5-IP7 keeps cellular MYC levels in check. Elevation in MYC downstream to 5-IP7 depletion influences cell fate in response to environmental cues. For further information see the article in this issue by Lolla and colleagues (pp. 1647–1661). Image was created by Akruti Shah using BioRender.
Review Article|
April 21 2021
Anti-glycan antibodies: roles in human disease
J. Sebastian Temme;
J. Sebastian Temme
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, U.S.A
Search for other works by this author on:
Dorothy L. Butler;
Dorothy L. Butler
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, U.S.A
Search for other works by this author on:
Jeffrey C. Gildersleeve
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, U.S.A
Correspondence: Jeffrey C. Gildersleeve ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 25 2021
Revision Received:
March 23 2021
Accepted:
March 26 2021
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2021
Biochem J (2021) 478 (8): 1485–1509.
Article history
Received:
January 25 2021
Revision Received:
March 23 2021
Accepted:
March 26 2021
Citation
J. Sebastian Temme, Dorothy L. Butler, Jeffrey C. Gildersleeve; Anti-glycan antibodies: roles in human disease. Biochem J 30 April 2021; 478 (8): 1485–1509. doi: https://doi.org/10.1042/BCJ20200610
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
View past webinars > |